Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis in Drug-Discovery Deal With Schering-Plough

NEW YORK, Aug. 6 – NeoGenesis and Schering-Plough Corporation have partnered to discover small-molecule drug leads, the companies announced on Monday.

Under the deal, NeoGenesis will employ its Automated Ligand Identification System (ALIS) and its neoMorph compound library to help Schering-Plough discover a range of antiviral candidates. In exchange, the drug giant will outlay research and development funding as well as an undisclosed equity investment in NeoGenesis.

The deal, which may run for five years, also provides NeoGenesis license fees and payments for clinical or regulatory milestones. It was not clear what those milestones are, and representatives from the Cambridge, Mass.-based company were not immediately available for comment.

“We are very pleased to enter this collaboration with Schering-Plough,” Satish Jindal, president and CSO of NeoGenesis, said in a statement. He expects the partnership to yield “high-quality leads” to “a variety” of Schering targets. 

In June, NeoGenesis and UK-based biotechnology company Oxford Glycosciences entered into a similar partnership.  

Under that deal, OGS, of Oxford, provided an undisclosed number of protein targets to NeoGenesis as well as pay NeoGenesis research fees, milestone payments, and royalties for any lead compounds. 

OGS, which will commercialize these compounds, also made an undisclosed equity investment in NeoGenesis. 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.